title: Differential activation of MAP kinase family members triggered by CD99 engagement.
abstract: The molecular basis for the modulatory properties of CD99 is not well understood. Treatment of human Jurkat T lymphocytes with anti-CD99 antibody led to activation of three mitogen-activated protein kinase (MAPK) members, ERK, JNK, and p38 MAPK, along with homotypic aggregation. While phosphorylation of ERK and JNK was inhibited by the pretreatment of a PKC inhibitor, bisindolylmaleimide I, activation of p38 MAPK was upregulated by the same pretreatment. The signaling pathways to MAPKs by CD99 engagement were independent of PI-3 kinase, distinguishing from those by CD3 engagement. Among MAPKs, ERK pathway was essential for homotypic aggregation together with intracytoplasmic Ca(2+).
authors.affiliation: Department of Microbiology, Sungkyunkwan University School of Medicine, Suwon, South Korea.
authors.forename: M J
authors.initials: MJ
authors.lastname: Hahn
authors.forename: S S
authors.initials: SS
authors.lastname: Yoon
authors.forename: H W
authors.initials: HW
authors.lastname: Sohn
authors.forename: H G
authors.initials: HG
authors.lastname: Song
authors.forename: S H
authors.initials: SH
authors.lastname: Park
authors.forename: T J
authors.initials: TJ
authors.lastname: Kim
mesh_terms: D000911:Antibodies, Monoclonal / Q000276:immunology; D002118:Calcium / Q000037:antagonists & inhibitors / Q000378:metabolism; D017871:Calcium-Calmodulin-Dependent Protein Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism; D002448:Cell Adhesion; D002614:Chelating Agents / Q000494:pharmacology; D004533:Egtazic Acid / Q000031:analogs & derivatives / Q000494:pharmacology; D004789:Enzyme Activation; D006801:Humans; D018960:Hyaluronan Receptors / Q000276:immunology / Q000378:metabolism*; D048031:JNK Mitogen-Activated Protein Kinases; D019169:Jurkat Cells; D048369:MAP Kinase Kinase 1; D020935:MAP Kinase Signaling System; D019950:Mitogen-Activated Protein Kinase 1 / Q000378:metabolism; D048052:Mitogen-Activated Protein Kinase 3; D020929:Mitogen-Activated Protein Kinase Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism; D020928:Mitogen-Activated Protein Kinases / Q000378:metabolism*; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism; D000081082:Phosphoinositide-3 Kinase Inhibitors; D010766:Phosphorylation; D011493:Protein Kinase C / Q000037:antagonists & inhibitors / Q000378:metabolism; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism; D011940:Receptor Aggregation; D013601:T-Lymphocytes / Q000166:cytology / Q000201:enzymology; D048051:p38 Mitogen-Activated Protein Kinases
chemical_list: D000911:Antibodies, Monoclonal; D002118:Calcium; D017871:Calcium-Calmodulin-Dependent Protein Kinases; D002614:Chelating Agents; D004533:Egtazic Acid; D018960:Hyaluronan Receptors; D048031:JNK Mitogen-Activated Protein Kinases; D048369:MAP Kinase Kinase 1; D019950:Mitogen-Activated Protein Kinase 1; D048052:Mitogen-Activated Protein Kinase 3; D020929:Mitogen-Activated Protein Kinase Kinases; D020928:Mitogen-Activated Protein Kinases; D019869:Phosphatidylinositol 3-Kinases; D000081082:Phosphoinositide-3 Kinase Inhibitors; D011493:Protein Kinase C; D017346:Protein Serine-Threonine Kinases; D048051:p38 Mitogen-Activated Protein Kinases; C070379:1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester; C482125:MAP2K1 protein, human